Time to deterioration (TTD) in patient-reported outcomes in phase 3 AXis trial of axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC) Meeting Abstract
| Authors: | Cella, D.; Escudier, B.; Rini, B.; Chen, C.; Bhattacharyya, H.; Tarazi, J.; Rosbrook, B.; Kim, S.; Motzer, R. |
| Abstract Title: | Time to deterioration (TTD) in patient-reported outcomes in phase 3 AXis trial of axitinib vs sorafenib as second-line therapy for metastatic renal cell carcinoma (mRCC) |
| Meeting Title: | 16th ECCO - 36th ESMO - 30th ESTRO European Multidisciplinary Cancer Congress (EMCC 2011) |
| Journal Title: | European Journal of Cancer |
| Volume: | 47 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2011 Sep 23-27 |
| Meeting Location: | Stockholm, Sweden |
| ISSN: | 0959-8049 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2011-09-01 |
| Start Page: | S224 |
| Language: | English |
| ACCESSION: | WOS:000295752800773 |
| PROVIDER: | wos |
| DOI: | 10.1016/S0959-8049(11)71079-6 |
| Notes: | --- - Meeting Abstract: 3006 - European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical oncology, Advocacy and Care - SEP 23-27, 2011 - Stockholm, SWEDEN - "Source: Wos" |
